Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - interferon alfa-2a - injection - 3 miu/0.5 ml - interferon alfa-2a 3 miu/0.5 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 10 miu/ml;   - solution for injection - 10 miu/ml - active: interferon alfa-2b 10 miu/ml   excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - interferon alfa-2b 5 miu/ml;   - solution for injection - 5 miu/ml - active: interferon alfa-2b 5 miu/ml   excipient: albumin dibasic sodium phosphate glycine methyl hydroxybenzoate monobasic sodium phosphate monohydrate propyl hydroxybenzoate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 6 miu/ml;   - solution for injection - 6 miu/ml - active: interferon alfa-2b 6 miu/ml   excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (interferon alfa-2b - unii:43k1w2t1m6) - peginterferon alfa-2b 50 ug in 0.5 ml - pegintron® , as part of a combination regimen, is indicated for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease. - pegintron in combination with ribavirin and an approved hepatitis c virus (hcv) ns3/4a protease inhibitor is indicated in adult patients with hcv genotype 1 infection (see labeling of the specific hcv ns3/4a protease inhibitor for further information). - pegintron in combination with ribavirin is indicated in patients with genotypes other than 1, pediatric patients (3-17 years of age), or in patients with genotype 1 infection where use of an hcv ns3/4a protease inhibitor is not warranted based on tolerability, contraindications or other clinical factors. pegintron monotherapy should only be used in the treatment of chc in patients with compensated liver disease if there are contraindications to or significant intolerance of ribavirin and is indicated for use only in previously untreated adult patients. combination therapy provides substantially better respons

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - interferon alpha-2c 15 µg/ml - injection with diluent - 15 mcg/ml - active: interferon alpha-2c 15 µg/ml excipient: water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - interferon alpha-2c 3 µg/ml - injection with diluent - 3 mcg/ml - active: interferon alpha-2c 3 µg/ml excipient: water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - interferon alpha-2c 6 µg/ml - injection with diluent - 6 mcg/ml - active: interferon alpha-2c 6 µg/ml excipient: water for injection

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - interferon alfa-2a 6000000 iu/ml - solution for injection in pre-filled syringe - 3 miu - interferon alfa-2a 3000000 iu - interferon alfa-2a

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - interferon alfa-2a 12000000 iu/ml - solution for injection in pre-filled syringe - 6 miu - interferon alfa-2a 6000000 iu - interferon alfa-2a